Fred Kurland - Dec 5, 2022 Form 4 Insider Report for Aridis Pharmaceuticals, Inc. (ARDS)

Role
Chief Financial Officer
Signature
/s/ Fred Kurland
Stock symbol
ARDS
Transactions as of
Dec 5, 2022
Transactions value $
$0
Form type
4
Date filed
12/7/2022, 07:59 AM
Previous filing
Oct 5, 2021
Next filing
Jun 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARDS Restricted Stock Units Award $0 +8K $0.00 8K Dec 5, 2022 Common Stock 8K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 4,000 shares of Common Stock will vest on June 5, 2023 and 4,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.